RxDoctor Payments Data

Bane Smith, MD

Family Medicine · Dallas, TXNPI 1790703098

Payments from drug & device makers

$655in general payments, 2019–2025

Across 43 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$178
  • Novartis$123
  • Boston Scientific$88
  • Novo Nordisk$63
  • GSK$57
  • AstraZeneca$26
  • plus $121 from 7 others

What the payments were for

  • Food & beverage$655100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$655 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$79,192
Medicare patients
306
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin127$177,060
OzempicSemaglutide66$78,121
EliquisApixaban62$58,977
FarxigaDapagliflozin Propanediol42$50,432
JanuviaSitagliptin Phosphate26$34,067
RybelsusSemaglutide15$33,335
TrulicityDulaglutide20$21,307
MounjaroTirzepatide11$13,948
XareltoRivaroxaban14$11,911
LinzessLinaclotide14$10,289
SymbicortBudesonide/Formoterol Fumarate34$9,713
Advair HfaFluticasone Propion/Salmeterol20$7,589
Breo ElliptaFluticasone/Vilanterol11$7,554
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$6,861
Atorvastatin Calcium854$6,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$63$111,45581 claims
AstraZenecaFarxiga, Symbicort$26$60,14576 claims
PfizerEliquis$11$58,97762 claims
MerckJanuvia$12$34,06726 claims
GSKBreo Ellipta, Incruse Ellipta$57$11,75924 claims
AbbVieLinzess$15$10,28914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →